S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Autolus Therapeutics Stock Forecast, Price & News

-0.10 (-1.53 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $6.44
50-Day Range
MA: $8.02
52-Week Range
Now: $6.44
Volume994,734 shs
Average Volume918,093 shs
Market Capitalization$336.49 million
P/E RatioN/A
Dividend YieldN/A
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:AUTL
Year FoundedN/A



Sales & Book Value

Annual Sales$2.91 million
Book Value$5.67 per share


Net Income$-123,850,000.00
Net Margins-8,652.90%


Market Cap$336.49 million
Next Earnings Date3/4/2021 (Confirmed)
OptionableNot Optionable


Overall MarketRank

1.17 out of 5 stars

Medical Sector

879th out of 1,960 stocks

Biological Products, Except Diagnostic Industry

113th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.10 (-1.53 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Autolus Therapeutics?

Wall Street analysts have given Autolus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Autolus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Autolus Therapeutics

How can I listen to Autolus Therapeutics' earnings call?

Autolus Therapeutics will be holding an earnings conference call on Thursday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.01. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.31 million. Autolus Therapeutics had a negative trailing twelve-month return on equity of 54.01% and a negative net margin of 8,652.90%.
View Autolus Therapeutics' earnings history

How has Autolus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AUTL stock has decreased by 4.9% and is now trading at $6.44.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AUTL?

8 analysts have issued twelve-month price objectives for Autolus Therapeutics' stock. Their forecasts range from $9.00 to $38.00. On average, they expect Autolus Therapeutics' share price to reach $21.71 in the next year. This suggests a possible upside of 237.2% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 57)
  • Dr. Martin Pulé, Founder, Sr. VP, Chief Scientific Officer & Director (Age 49)
  • Mr. Andrew J. Oakley, CFO & Sr. VP (Age 59)
  • Mr. Christopher Vann, Sr. VP & COO (Age 56)
  • Mr. David Brochu, Chief Technical Officer (Age 63)
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 56)
  • Dr. Muhammad Al-Hajj Ph.D., Sr. VP of Translational Sciences (Age 50)
  • Dr. Lucinda Crabtree Ph.D., VP of IR & Corp. Communications
  • Mr. Vishal Mehta, VP & Head of Clinical Operations
  • Dr. Nushmia Khokhar, Sr. VP of Clinical Devel.

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Schroder Investment Management Group (3.20%), Baker BROS. Advisors LP (1.50%), BlackRock Inc. (0.57%), JPMorgan Chase & Co. (0.49%), Renaissance Technologies LLC (0.15%) and Victory Capital Management Inc. (0.15%).

Which major investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Victory Capital Management Inc..

Which major investors are buying Autolus Therapeutics stock?

AUTL stock was bought by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Schroder Investment Management Group, JPMorgan Chase & Co., Pendal Group Limited, Renaissance Technologies LLC, and Wells Fargo & Company MN.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $6.44.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $336.49 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 290 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

Where are Autolus Therapeutics' headquarters?

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]

This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.